www.fdanews.com/articles/198003-gilead-sciences-kicks-off-phase-1-trial-of-inhaled-remdesivir-for-covid-19
Gilead Sciences Kicks Off Phase 1 Trial of Inhaled Remdesivir for COVID-19
July 10, 2020
Gilead Sciences has begun a phase 1 trial in the U.S. of an inhaled formulation of its COVID-19 antiviral remdesivir in healthy volunteers.
The initial trial will evaluate the drug in 60 participants aged 18-45. The next stage will study the formulation in COVID-19 patients who have not been hospitalized.
The inhaled formulation of the antiviral drug would be a better delivery option for non-hospitalized COVID-19 patients, the company said.